amrinone has been researched along with Cardiomyopathy, Hypertrophic Obstructive in 3 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amrinone, 100 mg orally every 8 hours, was administered to 13 patients with moderate-to-severe congestive heart failure (CHF) for 1 month on an outpatient basis to determine the beneficial and undesirable effects of this new cardioactive agent in this clinical setting." | 9.05 | Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. ( Bashore, TM; Dalpiaz, K; Hermiller, JB; Huss, P; Leier, CV; Magorien, RD; Unverferth, DV, 1983) |
| "Amrinone, 100 mg orally every 8 hours, was administered to 13 patients with moderate-to-severe congestive heart failure (CHF) for 1 month on an outpatient basis to determine the beneficial and undesirable effects of this new cardioactive agent in this clinical setting." | 5.05 | Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. ( Bashore, TM; Dalpiaz, K; Hermiller, JB; Huss, P; Leier, CV; Magorien, RD; Unverferth, DV, 1983) |
| " Amrinone was administered to improve the features of congestive heart failure induced by retention of body fluid." | 3.70 | [General anesthesia for a patient with primary aldosteronism complicated with hypertrophic nonobstructive cardiomyopathy]. ( Kinoshita, T; Matsuda, T; Shigemi, K; Shimosato, G; Tanaka, Y, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leier, CV | 1 |
| Dalpiaz, K | 1 |
| Huss, P | 1 |
| Hermiller, JB | 1 |
| Magorien, RD | 1 |
| Bashore, TM | 1 |
| Unverferth, DV | 1 |
| Nakajima, Y | 1 |
| Hayashi, Y | 1 |
| Miyashita, T | 1 |
| Horinouchi, N | 1 |
| Ohnishi, Y | 1 |
| Kuro, M | 1 |
| Shimosato, G | 1 |
| Matsuda, T | 1 |
| Shigemi, K | 1 |
| Kinoshita, T | 1 |
| Tanaka, Y | 1 |
1 trial available for amrinone and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy.
Topics: Aminopyridines; Amrinone; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Female; Heart Failure; H | 1983 |
2 other studies available for amrinone and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
[Anesthetic management of patients undergoing implantation of left ventricular assist system].
Topics: Adolescent; Adult; Amrinone; Anesthesia, Intravenous; Anesthetics, Intravenous; Cardiomyopathy, Dila | 1999 |
[General anesthesia for a patient with primary aldosteronism complicated with hypertrophic nonobstructive cardiomyopathy].
Topics: Adrenal Glands; Adult; Amrinone; Anesthesia, General; Cardiomyopathy, Hypertrophic; Heart Failure; H | 1999 |